Drugs / NeoAntigen Tumor Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03807102 | Jan 2024 → Jan 2025 | lung cancer | Yongchang Zhang | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05227378 | Mar 2022 → Mar 2025 | gastric cancer | Shen Lin | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | neoantigen tumor vaccine | “NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).” NCT03807102 ↗ |
| Action | Deplete | “Tumor vaccines may make the body build an immune response to kill tumor cells.” NCT03807102 ↗ |
| Modality | Vaccine | “NeoAntigen Tumor Vaccine” NCT03807102 ↗ |
| Route | Subcutaneous | “patients receive neoantigen tumor vaccine hypodermically” NCT03807102 ↗ |